Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of carbetocin injection 100 mcg/ml in China. Welcome to wholesale bulk high quality carbetocin injection 100 mcg/ml for sale here from our factory. Good service and reasonable price are available.
Carbetocin Injection 100 mcg/ml, as a long-acting oxytocin receptor agonist, is a key medication in the field of obstetrics for the prevention and treatment of postpartum hemorrhage. Its core mechanism revolves around uterine contraction and vascular compression, leveraging its potent, sustained, and stable properties to fundamentally control and prevent postpartum hemorrhage, reduce bleeding-related risks, and provide robust protection for the safety of both mother and infant after delivery. The following provides a detailed explanation of its role in preventing and treating postpartum hemorrhage from two aspects: core functions and core advantages.
Our Product Forms
|
|
|
| Carbetocin Injection | Carbetocin Tablet |
Carbetocin COA
 |
||
| Certificate of Analysis | ||
| Compound name | Carbetocin | |
| Grade | Pharmaceutical grade | |
| CAS No. | 37025-55-1 | |
| Quantity | 36g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090066 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
|
|
||
| Chemical Formula | C45H69N11O12S |
| Exact Mass | 987.48 |
| Molecular Weight | 988.17 |
| m/z | 987.48 (100.0%), 988.49 (48.7%), 989.49 (11.6%), 989.48 (4.5%), 988.48 (4.1%), 989.49 (2.5%), 990.48 (2.2%), 989.49 (2.0%), 990.49 (1.2%) |
| Elemental Analysis | C, 54.70; H, 7.04; N, 15.59; O, 19.43; S, 3.24 |
Carbetocin can accurately prevent and control postpartum hemorrhage
Potently Triggers Sustained Uterine Contractions: Carbetocin Injection 100 mcg/ml precisely binds to oxytocin receptors on uterine smooth muscle, rapidly initiating uterine contractions and maintaining strong, rhythmic, and sustained contraction states. One of the primary causes of postpartum hemorrhage is uterine atony, where the womb fails to effectively compress blood vessels to achieve hemostasis. By activating uterine contraction function, this medication addresses the root cause of uterine atony, laying the foundation for hemostasis.
Physically Compresses and Closes Blood Vessels to Achieve Hemostasis: When the womb contracts continuously under the influence of the medication, it exerts strong compression on the arteries and veins running through the myometrium. This compresses and closes the vascular openings at the placental separation site, directly blocking bleeding pathways, rapidly reducing blood loss, and achieving immediate hemostatic results, effectively curbing the progression of postpartum hemorrhage.
Maintains Stable Uterine Contractions to Prevent Recurrent Bleeding: Unlike short-acting uterotonic drugs, it sustains effective uterine contraction tension over an extended period, preventing recurrent bleeding caused by diminished or lost contractions. Its prolonged contractile result consolidates hemostatic outcomes, covering the high-risk period for postpartum hemorrhage, achieving long-term prevention and control, and reducing the risk of secondary bleeding.
This drug lays the foundation for hemostasis
It addresses the root cause of uterine atony, laying the foundation for hemostasis, for the following specific reasons:
Precisely Targets the Core Mechanism of Contraction
As an oxytocin receptor agonist, Carbetocin Injection 100 mcg/ml directly and specifically binds to oxytocin receptors on the uterine smooth muscle. It activates the signaling pathway for uterine contractions at its source without needing other intermediaries, initiating contractions from the very start of the mechanism, rather than merely alleviating the symptoms of weakness.
Maintains Long-Acting Uterine Tone
Unlike short-acting uterotonics, it continuously activates the receptors, preventing any interruption in the contraction signal. This ensures that the intensity of the uterine contractions is sufficient and their duration is prolonged, fundamentally resolving the core issues of "insufficient and unsustained contractions" and eliminating the risk of hemorrhage caused by uterine atony.
Directly Targets the Root Cause of Bleeding
The core pathogenesis of postpartum hemorrhage follows the logic of "uterine atony → inability to close blood vessels → bleeding." By directly resolving the predisposing factor of "uterine atony," It breaks this chain of bleeding. Instead of merely reacting to stop bleeding after it has occurred, it prevents hemorrhage at its source, thereby representing a fundamental approach to prevention and control.
Long term effectiveness of Carbetocin
This is able to maintain effective uterine contraction tension for an extended period. The core reasons for this long-acting result are as follows:
Optimized Molecular Structure for a Longer Half-Life
This medicine has undergone structural modification. Compared to short-acting uterotonics, its metabolic rate in the body is significantly slowed, leading to a substantially prolonged half-life. A single dose can exert its results continuously, avoiding the interruption of contractions caused by rapidly diminishing efficacy, thereby providing long-lasting support for the prevention and control of postpartum hemorrhage.
Strong and Sustained Receptor Binding Affinity
It forms a stable bond with oxytocin receptors on the uterine smooth muscle and is not easily dissociated. This allows for the continuous activation of contraction signaling pathways, ensuring the womb consistently maintains effective contraction tension. Instead of triggering brief contractions that quickly wear off, it achieves prolonged uterine contraction at a mechanistic level.
Smooth and Steady Drug Release
It is released at a steady rate within the body, acting on the uterine smooth muscle persistently and stably. This avoids the significant fluctuations in efficacy and rapid decline associated with short-acting drugs. It can sustain effective contraction intensity over a long period, effectively covering the high-risk period for postpartum hemorrhage and preventing recurrent bleeding.
Compared to regular uterine contraction drugs
Long Duration of Action Eliminates the Need for Frequent Dosing.This medicine has a significantly longer half-life than conventional oxytocin. Thanks to its optimized molecular structure, its metabolic rate in the body is greatly slowed. A single dose maintains its result for an extended period, continuously driving uterine smooth muscle contractions without the need for frequent additional doses like traditional short-acting uterotonics. This advantage not only effectively reduces the clinical workload for medical staff by minimizing the complexity of repeated administrations but, more importantly, ensures that the drug's result consistently covers the high-risk period for postpartum hemorrhage-the first two hours after delivery (the peak time for postpartum bleeding). It prevents the weakening of contractions caused by rapidly diminishing drug efficacy or delayed administration, thereby averting rebound bleeding or uncontrolled hemorrhage, and provides stable pharmacological support for long-term postpartum hemorrhage prevention and control.
Powerful, Steady, and Controllable Contractile result.As a long-acting oxytocin receptor agonist, this drug forms a stable and potent bond with oxytocin receptors on the uterine smooth muscle. It induces uterine contractions of sufficient intensity to quickly overcome uterine atony, promptly compress the blood vessels within the uterine myometrium, and rapidly achieve hemostasis. Its hemostatic efficacy is far superior to that of some short-acting uterotonics. At the same time, its contractile result is steady and controllable, avoiding dramatic peaks and troughs in efficacy.This ensures sufficient contractile intensity for hemostasis while effectively preventing adverse effects associated with excessively strong, frequent, or highly fluctuating contractions, such as uterine rupture or severe postpartum abdominal pain.
This makes the hemostasis process safer and more reliable, and also reduces maternal discomfort after delivery.High Targeting Specificity for Efficient Hemostasis.This medicine possesses high targeting specificity, primarily focusing on oxytocin receptors in the uterine smooth muscle. It precisely targets the core element of postpartum hemorrhage prevention and control, enabling it to concentrate its contractile and hemostatic results efficiently, thus avoiding action on other organs or systems.Compared to some traditional uterotonics that may have potential impacts on the cardiovascular or digestive systems.
Carbetocin's targeting advantage significantly reduces non-specific effects.While enhancing hemostatic efficiency, it lowers the potential for side results, making postpartum hemorrhage prevention and control more targeted and safer, especially suitable for parturients who are physically weakened or have low drug tolerance after delivery.Rapid Onset of Action for Timely Risk Control.Although it is a long-acting drug, its onset of action is not compromised. After administration, it rapidly penetrates the uterine smooth muscle tissue, quickly binds to oxytocin receptors, activates the uterine contraction signaling pathway, and swiftly initiates uterine contractions.
Postpartum hemorrhage often occurs within a short time after fetal delivery. Delayed hemostasis can rapidly escalate into massive bleeding, endangering the safety of both mother and infant.It's rapid onset allows for timely intervention in the initial stage of postpartum hemorrhage, quickly reducing blood loss, and seizing critical time to prevent and control severe postpartum hemorrhage.It effectively curbs the progression of bleeding, further reducing the risk of bleeding-related severe complications such as anemia and shock.
Enhanced Safety in Prevention and Control, Reduced Bleeding Risk.With its potent, long-lasting, and stable uterotonic and hemostatic results, Carbetocin Injection 100 mcg/ml enhances the safety of postpartum hemorrhage prevention and control from multiple aspects, effectively reducing the incidence of massive postpartum hemorrhage. On one hand, its long-acting and steady contractile result fundamentally reduces bleeding caused by uterine atony.On the other hand, its high targeting specificity and low side result profile minimize bleeding-related risks indirectly caused by adverse drug reactions.
Simultaneously, this drug effectively reduces the total blood loss from postpartum hemorrhage, lowering the risk of severe complications like anemia, shock, and puerperal infection due to excessive blood loss. It reduces the need for blood transfusions, alleviates the postpartum physical burden on the mother, and provides comprehensive protection for maternal and infant health in the postpartum period, further elevating the overall standard of postpartum hemorrhage prevention and control in obstetrics.
FAQ
1.What is the difference between oxytocin and carbetocin?
The use of carbetocin appears to be simpler, with a prolonged duration of action of 5 h, compared to 1.5 h for oxytocin, and avoids repeated injections to treat uterine atony. Much evidence in the literature proves the efficacy of carbetocin over oxytocin in both vaginal and caesarean deliveries.
2.What type of drug is carbetocin?
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the womb.
Hot Tags: carbetocin injection 100 mcg/ml, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale